Prevention and Treatment of Contrast-Induced Nephropathy

Techniques in Vascular and Interventional Radiology

Volumn 9, Issue 2, 2006, Pages 42-49

  Al Ghonaim, Mohammed ^a   Pannu, Neesh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

contrast induced nephropathy; prevention; treatment

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CARBON DIOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FENOLDOPAM; GADOLINIUM; GASTROGRAFFIN; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; IOTALAMATE SODIUM; IOTROLAN; IOVERSOL; IOXAGLIC ACID; MEGLUMINE DIATRIZOATE; MEGLUMINE IOXAGLATE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; PLACEBO; THEOPHYLLINE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FORMULATION; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY DISEASE; LENGTH OF STAY; META ANALYSIS; MORTALITY; NEPHROTOXICITY; PATHOGENESIS; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; VISCOSITY;

CONTRAST MEDIA; HUMANS; KIDNEY FAILURE, ACUTE; RISK FACTORS;

EID: 34247588690     PISSN: 10892516     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.tvir.2006.12.002     Document Type: Article

References (94)

1. Maitino A.J., Levin D.C., Parker L., et al. Practice patterns of radiologists and nonradiologists in utilization of noninvasive diagnostic imaging among the Medicare population 1993-1999. Radiology 228 3 (2003) 795-801
2. Toms A.P., Cash C.J., Linton S.J., et al. Requests for body computed tomography: increasing workload, increasing indications and increasing age. Eur Radiol 11 12 (2001) 2633-2637
3. Lameire N., Van Biesen W., and Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2 7 (2006) 364-377
4. Gleeson T.G., and Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 183 6 (2004) 1673-1689
5. Rudnick M.R., Goldfarb S., Wexler L., et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 47 1 (1995) 254-261
6. McCullough P.A., Wolyn R., Rocher L.L., et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103 5 (1997) 368-375
7. Levy E.M., Viscoli C.M., and Horwitz R.I. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275 19 (1996) 1489-1494
8. van Acker B.A., Koomen G.C., Koopman M.G., et al. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 340 8831 (1992) 1326-1329
9. Andreev E., Koopman M., and Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?. J Intern Med 246 3 (1999) 247-252
10. Hoffmann U., Fischereder M., Kruger B., et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15 2 (2004) 407-410
11. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 2 suppl 1 (2002) S1-S266
12. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 1 (1976) 31-41
13. Thomas L., and Huber A.R. Renal function-estimation of glomerular filtration rate. Clin Chem Lab Med 44 11 (2006) 1295-1302
14. Filler G., Foster J., Acker A., et al. The Cockcroft-Gault formula should not be used in children. Kidney Int 67 6 (2005) 2321-2324
15. Poggio E.D., Wang X., Greene T., et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16 2 (2005) 459-466
16. Levey A.S. Assessing the effectiveness of therapy to prevent the progression of renal disease. Am J Kidney Dis 22 1 (1993) 207-214
17. Cirillo M., Anastasio P., and De Santo N.G. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 20 9 (2005) 1791-1798
18. Herget-Rosenthal S., Pietruck F., Volbracht L., et al. Serum cystatin C-a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol 64 1 (2005) 41-446
19. Wells M., and Lipman J. Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. S Afr J Surg 35 1 (1997) 20-23
20. Detrenis S., Meschi M., Musini S., et al. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 20 8 (2005) 1542-1550
21. Pflueger A., Larson T.S., Nath K.A., et al. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 75 12 (2000) 1275-1283
22. Cantley L.G., Spokes K., Clark B., et al. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 44 6 (1993) 1217-1223
23. Agmon Y., Peleg H., Greenfeld Z., et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 94 3 (1994) 1069-1075
24. Persson P.B., Hansell P., and Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 68 1 (2005) 14-22
25. Liss P., Aukland K., Carlsson P.O., et al. Influence of iothalamate on renal medullary perfusion and oxygenation in the rat. Acta Radiol 46 8 (2005) 823-839
26. Liss P., Persson P.B., Hansell P., et al. Renal failure in 57,925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 70 (2006) 1811-1817
27. Spargias K., Alexopoulos E., Kyrzopoulos S., et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110 18 (2004) 2837-2842
28. Lasser E.C., Lyon S.G., and Berry C.C. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 203 3 (1997) 605-610
29. Moore R.D., Steinberg E.P., Powe N.R., et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 182 3 (1992) 649-655
30. Mueller C., Seidensticker P., Buettner H.J., et al. Incidence of contrast nephropathy in patients receiving comprehensive intravenous and oral hydration. Swiss Med Wkly 135 19-20 (2005) 286-290
31. Mehran R., Aymong E.D., Nikolsky E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44 7 (2004) 1393-1399
32. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 19 (2002) 2259-2264
33. Freeman R.V., O'Donnell M., Share D., et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 90 10 (2002) 1068-1073
34. Bartholomew B.A., Harjai K.J., Dukkipati S., et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93 12 (2004) 1515-1519
35. Parfrey P.S., Griffiths S.M., Barrett B.J., et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320 3 (1989) 143-149
36. Thomsen H.S., Morcos S.K., and ESUR Contrast Media Safety Committee. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. Eur Radiol 9 4 (1999) 738-740
37. Pannu N., Wiebe N., and Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 295 23 (2006) 2765-2779
38. Barrett B.J., and Carlisle E.J. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188 1 (1993) 171-178
39. Aspelin P., Aubry P., Fransson S.G., et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348 6 (2003) 491-499
40. Jo S.H., Youn T.J., Koo B.K., et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol 48 5 (2006) 924-930
41. Chalmers N., and Jackson R.W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 72 859 (1999) 701-703
42. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 68 5 (2005) 2256-2263
43. Barrett B.J., Parfrey P.S., McDonald J.R., et al. Nonionic low-osmolality versus ionic high-osmolality contrast material for intravenous use in patients perceived to be at high risk: randomized trial. Radiology 183 1 (1992) 105-110
44. Schwab S.J., Hlatky M.A., Pieper K.S., et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 320 3 (1989) 149-153
45. Harris K.G., Smith T.P., Cragg A.H., et al. Nephrotoxicity from contrast material in renal insufficiency: ionic versus nonionic agents. Radiology 179 3 (1991) 849-852
46. Manske C.L., Sprafka J.M., Strony J.T., et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89 5 (1990) 615-620
47. Nikolsky E., Mehran R., Lasic Z., et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 67 2 (2005) 706-713
48. Cigarroa R.G., Lange R.A., Williams R.H., et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 86 6 Pt. 1 (1989) 649-652
49. Thomsen H.S. How to avoid CIN: guidelines from the European Society of Urogenital Radiology. Nephrol Dial Transplant 20 suppl 1 (2005) i18-i22
50. American College of Radiology. Manual on contrast media, version 5.0 (accessed November 08, 2006). [cited; Available from: https://sso.acr.org]
51. Canadian Association of Radiologists: Guidelines for the Prevention of Contrast Induced Nephropathy 2006 (accessed November 08, 2006). [cited; Available from: http://www.car.ca]
52. Panel T.C.C.W. Contrast-induced nephropathy: clinical insights and practical guidance. Am J Cardiol 98 6 (2006) 2-77
53. Bader B.D., Berger E.D., Heede M.B., et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?. Clin Nephrol 62 1 (2004) 1-7
54. Krasuski R.A., Beard B.M., Geoghagan J.D., et al. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol 15 12 (2003) 699-702
55. Merten G.J., Burgess W.P., Gray L.V., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 19 (2004) 2328-2334
56. Mueller C., Buerkle G., Buettner H.J., et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162 3 (2002) 329-336
57. Taylor A.J., Hotchkiss D., Morse R.W., et al. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 114 6 (1998) 1570-1574
58. Trivedi H.S., Moore H., Nasr S., et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93 1 (2003) C29-C34
59. Stevens M.A., McCullough P.A., Tobin K.J., et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 33 2 (1999) 403-411
60. Weinstein J.M., Heyman S., and Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 62 4 (1992) 413-415
61. Solomon R., Werner C., Mann D., et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331 21 (1994) 1416-1420
62. Dussol B., Morange S., Loundoun A., et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 21 8 (2006) 2120-2126
63. Gare M., Haviv Y.S., Ben-Yehuda A., et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 34 6 (1999) 1682-1688
64. Hans S.S., Hans B.A., Dhillon R., et al. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 64 5 (1998) 432-436
65. Weisberg L.S., Kurnik P.B., and Kurnik B.R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 45 1 (1994) 259-265
66. Abizaid A.S., Clark C.E., Mintz G.S., et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83 2 (1999) 260-263 A5
67. Bakris G.L., Lass N.A., and Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int 56 1 (1999) 206-210
68. Tumlin J.A., Wang A., Murray P.T., et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 143 5 (2002) 894-903
69. Stone G.W., McCullough P.A., Tumlin J.A., et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290 17 (2003) 2284-2291
70. Briguori C., Colombo A., Airoldi F., et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44 4 (2004) 762-765
71. Ng T.M., Shurmur S.W., Silver M., et al. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). Int J Cardiol 109 3 (2006) 322-328
72. Ix J.H., McCulloch C.E., and Chertow G.M. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 19 11 (2004) 2747-2753
73. Erley C.M., Duda S.H., Schlepckow S., et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 45 5 (1994) 1425-1431
74. Erley C.M., Duda S.H., Rehfuss D., et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 14 5 (1999) 1146-1149
75. Gandhi M.R., Brown P., Romanowski C.A., et al. The use of theophylline, an adenosine antagonist in the prevention of contrast media induced nephrotoxicity. Br J Radiol 65 777 (1992) 838
76. Huber W., Ilgmann K., Page M., et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 223 3 (2002) 772-779
77. Huber W., Schipek C., Ilgmann K., et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 91 10 (2003) 1157-1162
78. Kapoor A., Kumar S., Gulati S., et al. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 17 11 (2002) 1936-1941
79. Bagshaw S.M., and Ghali W.A. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 165 10 (2005) 1087-1093
80. Marenzi G., Assanelli E., Marana I., et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354 26 (2006) 2773-2782
81. Morcos S.K., Thomsen H.S., and Webb J.A. Dialysis and contrast media. Eur Radiol 12 12 (2002) 3026-3030
82. Huber W., Jeschke B., Kreymann B., et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol 37 9 (2002) 471-481
83. Vogt B., Ferrari P., Schonholzer C., et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111 9 (2001) 692-698
84. Frank H., Werner D., Lorusso V., et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 60 3 (2003) 176-182
85. Marenzi G., and Bartorelli A.L. Hemofiltration in the prevention of radiocontrast agent induced nephropathy. Minerva Anestesiol 70 4 (2004) 189-191
86. Marenzi G., Marana I., Lauri G., et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349 14 (2003) 1333-1340
87. Klarenbach S.W., Pannu N., Tonelli M.A., et al. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care Med 34 4 (2006) 1044-1051
88. Elicker B.M., Cypel Y.S., and Weinreb J.C. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. AJR Am J Roentgenol 186 6 (2006) 1651-1658
89. Nikolsky E., Aymong E.D., Dangas G., et al. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med 4 suppl 1 (2003) S7-S14
90. Tippins R.B., Torres W.E., Baumgartner B.R., et al. Are screening serum creatinine levels necessary prior to outpatient CT examinations?. Radiology 216 2 (2000) 481-484
91. Kerns S.R., and Hawkins Jr. I.F. Carbon dioxide digital subtraction angiography: expanding applications and technical evolution. AJR Am J Roentgenol 164 3 (1995) 735-741
92. Kessel D.O., Robertson I., Patel J.T., et al. Carbon-dioxide-guided vascular interventions: technique and pitfalls. Cardiovasc Intervent Radiol 25 6 (2002) 476-483
93. 2-enhanced renal angiography for diagnosis and percutaneous treatment. Radiology 210 3 (1999) 663-672
94. Ergun I., Keven K., Uruc I., et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21 3 (2006) 697-700